Literature DB >> 22374373

Potential impact of accelerating the primary dose of rotavirus vaccine in infants.

Elizabeth E Halvorson1, Timothy R Peters, Beverly M Snively, Katherine A Poehling.   

Abstract

We estimated the potential impact of administering the first dose of rotavirus vaccine at 6 weeks (42 days of life) instead of 2 months of age, which is permissible for all U.S. vaccines recommended at 2 months of age, on rotavirus hospitalization rates. We used published data for hospitalization rates, vaccine coverage, and vaccine efficacy after one dose and assumed a two-week delay in seroconversion after vaccine administration in the United States. Administering the first dose of rotavirus vaccine at 6 weeks instead of 8 weeks of age should have prevented 1110, 1660, and 2210 rotavirus hospitalizations among U.S. infants <3 months of age in 2006 when the vaccine was first introduced. This estimated benefit represents a 2-4% reduction in rotavirus hospitalizations among children <5 years of age.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374373      PMCID: PMC3312978          DOI: 10.1016/j.vaccine.2012.02.032

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

1.  Withdrawal of rotavirus vaccine recommendation.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-11-05       Impact factor: 17.586

2.  Annual summary of vital statistics: trends in the health of Americans during the 20th century.

Authors:  B Guyer; M A Freedman; D M Strobino; E J Sondik
Journal:  Pediatrics       Date:  2000-12       Impact factor: 7.124

3.  Severe pertussis in infants: estimated impact of first vaccine dose at 6 versus 8 weeks in australia.

Authors:  Alice Ruth Foxwell; Peter McIntyre; Helen Quinn; Katrina Roper; Mark S Clements
Journal:  Pediatr Infect Dis J       Date:  2011-02       Impact factor: 2.129

4.  Estimating the rotavirus hospitalization disease burden and trends, using capture-recapture methods.

Authors:  Mary Allen Staat; Marilyn A Rice; Stephanie Donauer; Daniel C Payne; Joseph S Bresee; T Christopher Mast; Aaron T Curns; Margaret M Cortese; Beverly Connelly; Monica McNeal; Richard L Ward; David I Bernstein; Umesh D Parashar; Shelia Salisbury
Journal:  Pediatr Infect Dis J       Date:  2010-12       Impact factor: 2.129

5.  Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states.

Authors:  Aaron T Curns; Claudia A Steiner; Marguerite Barrett; Katherine Hunter; Emily Wilson; Umesh D Parashar
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

6.  Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial.

Authors:  K Zaman; Duc Anh Dang; John C Victor; Sunheang Shin; Md Yunus; Michael J Dallas; Goutam Podder; Dinh Thiem Vu; Thi Phuong Mai Le; Stephen P Luby; Huu Tho Le; Michele L Coia; Kristen Lewis; Stephen B Rivers; David A Sack; Florian Schödel; A Duncan Steele; Kathleen M Neuzil; Max Ciarlet
Journal:  Lancet       Date:  2010-08-06       Impact factor: 79.321

7.  Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.

Authors:  George E Armah; Samba O Sow; Robert F Breiman; Michael J Dallas; Milagritos D Tapia; Daniel R Feikin; Fred N Binka; A Duncan Steele; Kayla F Laserson; Nana A Ansah; Myron M Levine; Kristen Lewis; Michele L Coia; Margaret Attah-Poku; Joel Ojwando; Stephen B Rivers; John C Victor; Geoffrey Nyambane; Abraham Hodgson; Florian Schödel; Max Ciarlet; Kathleen M Neuzil
Journal:  Lancet       Date:  2010-08-06       Impact factor: 79.321

8.  Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.

Authors:  Julie A Boom; Jacqueline E Tate; Leila C Sahni; Marcia A Rench; Jennifer J Hull; Jon R Gentsch; Manish M Patel; Carol J Baker; Umesh D Parashar
Journal:  Pediatrics       Date:  2010-01-18       Impact factor: 7.124

9.  Unexpectedly high burden of rotavirus gastroenteritis in very young infants.

Authors:  H Fred Clark; Amy E Marcello; Diane Lawley; Megan Reilly; Mark J DiNubile
Journal:  BMC Pediatr       Date:  2010-06-11       Impact factor: 2.125

10.  Effect of human rotavirus vaccine on severe diarrhea in African infants.

Authors:  Shabir A Madhi; Nigel A Cunliffe; Duncan Steele; Desirée Witte; Mari Kirsten; Cheryl Louw; Bagrey Ngwira; John C Victor; Paul H Gillard; Brigitte B Cheuvart; Htay H Han; Kathleen M Neuzil
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

View more
  2 in total

1.  Open-Label Pilot Study to Compare the Safety and Immunogenicity of Pentavalent Rotavirus Vaccine (RV5) Administered on an Early Alternative Dosing Schedule with Those of RV5 Administered on the Recommended Standard Schedule.

Authors:  Ezzeldin Saleh; Brian Eichner; Douglas W Clark; Martha E Gagliano; James M Troutman; Lynn Harrington; Monica McNeal; Dennis Clements
Journal:  J Pediatric Infect Dis Soc       Date:  2018-02-19       Impact factor: 3.164

2.  Public health impact of accelerated immunization against rotavirus infection among children aged less than 6 months in the United States.

Authors:  Derek Weycker; Mark Andrew Atwood; Baudouin Standaert; Girishanthy Krishnarajah
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.